Abstract
had adjuvant therapy including tamoxifen. 3 of 13 patients (23%) who performed from total mastectomy, and 1 of 2 patient (50%) who performed from partial mastectomy had recurrence or metastasis (p = 0.229). After recurrence, they were treated from EC (epirubicin + cyclophosphamide), TC (docetaxel + cyclophosphamide), letrozole, or abraxane, and 3 of them are alive, 1 of them is unknown. Conclusion: It is suggested that tamoxifen treatment as adjuvant therapy may improve disease free survival. Almost all patients are estrogen receptor positive atmale breast cancer, therefore tamoxifen can be effective at male breast cancer therapy. Disclosure of Interest: No significant relationships.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
